{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:25:35Z","timestamp":1792481135541,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04635-2","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:26Z","timestamp":1777688906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: from clinical trials to real-life practice"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Maratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Antonio","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Costanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pavese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Schinzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"4635_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0800-6","volume":"17","author":"H-Y Tan","year":"2018","unstructured":"H.-Y. Tan, N. Wang, W. Lam, W. Guo, Y. Feng, Y.-C. Cheng, Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol. Cancer 17, 43 (2018)","journal-title":"Mol. Cancer"},{"key":"4635_CR2","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Y. Shiravand, F. Khodadadi, S.M.A. Kashani, S.R. Hosseini-Fard, S. Hosseini, H. Sadeghirad, R. Ladwa, K. O\u2019Byrne, A. Kulasinghe, Immune checkpoint inhibitors in cancer therapy. Curr. Oncol. 29, 3044\u20133060 (2022)","journal-title":"Curr. Oncol."},{"key":"4635_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2019.05.015","volume":"141","author":"A Jannin","year":"2019","unstructured":"A. Jannin, N. Penel, M. Ladsous, M.C. Vantyghem, C. Do Cao, Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit. Rev. Oncol. Hematol. 141, 23\u201335 (2019)","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"4635_CR4","doi-asserted-by":"publisher","unstructured":"Shao W., Lu D., Yang K., Gao Y., Zhang J., Zhang Y. (2024) 7626 endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors: a retrospective analysis using the US FDA adverse event reporting system. J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvae163.1041","DOI":"10.1210\/jendso\/bvae163.1041"},{"key":"4635_CR5","doi-asserted-by":"publisher","unstructured":"Yang, L., Murthy, S., Cortellini, A., Lim, E., Gonzalez, M., Pinato, D., Abdel-Malek, M., Mahmoud, S., & Martin, N. (2024). Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival. Frontiers in Endocrinology, 15. https:\/\/doi.org\/10.3389\/fendo.2024.1369268.","DOI":"10.3389\/fendo.2024.1369268"},{"key":"4635_CR6","doi-asserted-by":"publisher","unstructured":"Zhai, Y., Ye, X., Hu, F., Xu, J., Guo, X., Zhuang, Y., & He, J. (2019). Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. J. Immunother. Cancer, 7. https:\/\/doi.org\/10.1186\/s40425-019-0754-2.","DOI":"10.1186\/s40425-019-0754-2"},{"key":"4635_CR7","doi-asserted-by":"publisher","unstructured":"Quan, L., Liu, J., Wang, Y., Yang, F., Yang, Z., Ju, J., Shuai, Y., Wei, T., Yue, J., Wang, X., et al (2024). Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization. Hum. Vaccin. Immunother, 20. https:\/\/doi.org\/10.1080\/21645515.2024.2410557.","DOI":"10.1080\/21645515.2024.2410557"},{"key":"4635_CR8","doi-asserted-by":"publisher","unstructured":"Liguori, L., Luciano, A., Polcaro, G., Ottaiano, A., Cascella, M., Perri, F., Pepe, S., & Sabbatino, F. (2023). Prior anti-angiogenic TKI-based treatment as potential predisposing factor to nivolumab-mediated recurrent thyroid disorder adverse events in mRCC patients: a case series. Biomedicines, 11. https:\/\/doi.org\/10.3390\/biomedicines11112974.","DOI":"10.3390\/biomedicines11112974"},{"key":"4635_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"L-S Chang","year":"2019","unstructured":"L.-S. Chang, R. Barroso-Sousa, S.M. Tolaney, F.S. Hodi, U.B. Kaiser, L. Min, Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40, 17\u201365 (2019)","journal-title":"Endocr. Rev."},{"key":"4635_CR10","doi-asserted-by":"publisher","unstructured":"Gao L., Yang X., Yi C., Zhu H. (2019) Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.01173","DOI":"10.3389\/fphar.2019.01173"},{"key":"4635_CR11","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3390\/cancers15072016","volume":"15","author":"C Mytareli","year":"2023","unstructured":"C. Mytareli, D.C. Ziogas, A. Karampela, P. Papalexis, V. Siampanopoulou, A. Lafioniatis, O. Benopoulou, H. Gogas, A. Angelousi, The uncharted landscape of rare endocrine immune-related adverse events. Cancers 15, 2016 (2023)","journal-title":"Cancers"},{"key":"4635_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"J.J. Wright, A.C. Powers, D.B. Johnson, Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 17, 389\u2013399 (2021)","journal-title":"Nat. Rev. Endocrinol."},{"key":"4635_CR13","doi-asserted-by":"publisher","unstructured":"Cardona Z., Sosman J.A., Chandra S., Huang W. (2023) Endocrine side effects of immune checkpoint inhibitors. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2023.1157805","DOI":"10.3389\/fendo.2023.1157805"},{"key":"4635_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100011","volume":"6","author":"SA Paschou","year":"2021","unstructured":"S.A. Paschou, K. Stefanaki, T. Psaltopoulou, M. Liontos, K. Koutsoukos, F. Zagouri, I. Lambrinoudaki, M.-A. Dimopoulos, How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open. 6, 100011 (2021)","journal-title":"ESMO Open."},{"key":"4635_CR15","doi-asserted-by":"publisher","unstructured":"O\u2019Reilly D., O\u2019Leary C.L., Reilly A., Teo M.Y., O\u2019Kane G., Hendriks L., Bennett K., Naidoo J. (2024) Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1380453","DOI":"10.3389\/fonc.2024.1380453"},{"key":"4635_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14737140.2024.2357814","volume":"24","author":"C Ciccarese","year":"2024","unstructured":"C. Ciccarese, A. Anghelone, A. Stefani, A. Cigliola, A. Strusi, F. D\u2019Agostino, E. Bria, R. Iacovelli, G. Tortora, The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis. Expert. Rev. Anticancer. Ther. 24, 623\u2013633 (2024)","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"4635_CR17","doi-asserted-by":"publisher","unstructured":"Sawada T., Narukawa M. (2024) A systematic review of treatment-related adverse events for combination therapy of multiple tyrosine kinase inhibitor and immune checkpoint inhibitor. Cancer Control. https:\/\/doi.org\/10.1177\/10732748241244586","DOI":"10.1177\/10732748241244586"},{"issue":"1","key":"4635_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/medicina61010123","volume":"61","author":"M D\u00f6kmeta\u015f","year":"2025","unstructured":"M. D\u00f6kmeta\u015f, H. Mu\u011flu, E. \u00d6zcan, B. Bayram Kuvvet, K. Helvac\u0131, E. Kalac\u0131, S. Kahraman, M.B. Aykan, \u0130. \u00c7i\u00e7in, F. Sel\u00e7ukbiricik et al. Endocrine adverse events in patients treated with immune checkpoint inhibitors: a comprehensive analysis. Medicina 61(1), 123 (2025). https:\/\/doi.org\/10.3390\/medicina61010123","journal-title":"Medicina"},{"issue":"6","key":"4635_CR19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"R. Barroso-Sousa, P.A. Ott, F.S. Hodi, U.B. Kaiser, S.M. Tolaney, L. Min, Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer 124(6), 1111\u20131121 (2018). https:\/\/doi.org\/10.1002\/cncr.31200","journal-title":"Cancer"},{"issue":"4","key":"4635_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.505","volume":"7","author":"O Elshafie","year":"2024","unstructured":"O. Elshafie, A.B. Khalil, B. Salman, A. Atabani, H. Al-Sayegh, Immune checkpoint inhibitors-induced endocrinopathies: assessment, management and monitoring in a comprehensive cancer centre. Endocrinol. Diabetes Metab. 7(4), e00505 (2024). https:\/\/doi.org\/10.1002\/edm2.505","journal-title":"Endocrinol. Diabetes Metab."},{"issue":"1","key":"4635_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"I. Puzanov, A. Diab, K. Abdallah, C.O. Bingham 3rd, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M.E. Lacouture, N.R. LeBoeuf et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J. Immunother. Cancer 5(1), 95 (2017). https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J. Immunother. Cancer"},{"key":"4635_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","volume":"15","author":"S Keam","year":"2024","unstructured":"S. Keam, N. Turner, F.G. Kugeratski, R. Rico, J. Colunga-Minutti, R. Poojary, S. Alekseev, A.B. Patel, Y.J. Li, A. Sheshadri et al. Toxicity in the era of immune checkpoint inhibitor therapy. Front. Immunol. 15, 1447021 (2024). https:\/\/doi.org\/10.3389\/fimmu.2024.1447021","journal-title":"Front. Immunol."},{"issue":"2","key":"4635_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.tem.2021.10.009","volume":"33","author":"S Chiloiro","year":"2022","unstructured":"S. Chiloiro, A. Bianchi, A. Giampietro, D. Milardi, L. De Marinis, A. Pontecorvi, The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. Trends Endocrinol. Metab. 33(2), 87\u2013104 (2022). https:\/\/doi.org\/10.1016\/j.tem.2021.10.009","journal-title":"Trends Endocrinol. Metab."},{"issue":"7","key":"4635_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"R.M. Ruggeri, A. Campenn\u00ec, G. Giuffrida, P. Trimboli, L. Giovanella, F. Trimarchi, S. Cannav\u00f2, Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J. Endocrinol. Invest. 42(7), 745\u2013756 (2019). https:\/\/doi.org\/10.1007\/s40618-018-0984-z","journal-title":"J. Endocrinol. Invest."},{"key":"4635_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102994","volume":"9","author":"T Powles","year":"2024","unstructured":"T. Powles, M. Burotto, B. Escudier et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 9, 102994 (2024)","journal-title":"ESMO Open."},{"key":"4635_CR26","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"B.I. Rini, E.R. Plimack, V. Stus et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019)","journal-title":"N. Engl. J. Med."},{"key":"4635_CR27","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.eururo.2023.08.010","volume":"84","author":"ER Plimack","year":"2023","unstructured":"E.R. Plimack, T. Powles, V. Stus et al. Corrigendum to \u201cpembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study\u201d [Eur. Urol. (2023)]. Eur. Urol. 84, e123\u2013e124 (2023)","journal-title":"Eur. Urol."},{"key":"4635_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101210","volume":"8","author":"JBAG Haanen","year":"2023","unstructured":"J.B.A.G. Haanen, J. Larkin, T.K. Choueiri et al. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the international metastatic renal cell carcinoma database consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 8, 101210 (2023)","journal-title":"ESMO Open."},{"key":"4635_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","volume":"35","author":"XQ Yan","year":"2024","unstructured":"X.Q. Yan, M.J. Ye, Q. Zou et al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann. Oncol. 35, 190\u2013199 (2024)","journal-title":"Ann. Oncol."},{"key":"4635_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.eururo.2024.02.014","volume":"86","author":"R Iacovelli","year":"2024","unstructured":"R. Iacovelli, C. Ciccarese, S. Buti et al. Avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma. the tide-A phase 2 study. Eur. Urol. 86, 411\u2013419 (2024)","journal-title":"Eur. Urol."},{"key":"4635_CR31","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","volume":"388","author":"TK Choueiri","year":"2023","unstructured":"T.K. Choueiri, T. Powles, L. Albiges et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N. Engl. J. Med. 388, 1767\u20131778 (2023)","journal-title":"N. Engl. J. Med."},{"key":"4635_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"T.K. Choueiri, T. Powles, M. Burotto et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829\u2013841 (2021)","journal-title":"N. Engl. J. Med."},{"key":"4635_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","volume":"6","author":"A Amin","year":"2018","unstructured":"A. Amin, E.R. Plimack, M.S. Ernstoff et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J. Immunother. Cancer 6, 109 (2018)","journal-title":"J. Immunother. Cancer"},{"key":"4635_CR34","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"R.J. Motzer, C. Porta, M. Eto et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J. Clin. Oncol. 42, 1222\u20131228 (2024)","journal-title":"J. Clin. Oncol."},{"key":"4635_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ygyno.2024.04.011","volume":"186","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2024","unstructured":"A. Gonz\u00e1lez-Mart\u00edn, H.C. Chung, E. Saada-Bouzid et al. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol. Oncol. 186, 182\u2013190 (2024)","journal-title":"Gynecol. Oncol."},{"key":"4635_CR36","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1002\/cncr.35387","volume":"130","author":"HC Chung","year":"2024","unstructured":"H.C. Chung, E. Saada\u2010Bouzid, F. Longo et al. Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple\u2010negative breast cancer: Results from the triple\u2010negative breast cancer cohort of the phase 2 LEAP\u2010005 Study. Cancer 130, 3278\u20133288 (2024)","journal-title":"Cancer"},{"key":"4635_CR37","doi-asserted-by":"publisher","first-page":"e007366","DOI":"10.1136\/jitc-2023-007366","volume":"11","author":"W Zhang","year":"2023","unstructured":"W. Zhang, S. Tong, B. Hu et al. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J. Immunother. Cancer 11, e007366 (2023)","journal-title":"J. Immunother. Cancer"},{"key":"4635_CR38","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1002\/cncr.35377","volume":"130","author":"T Ning","year":"2024","unstructured":"T. Ning, D. Li, T. Deng, Y. Bai, Y. Chen, Z. Wang, B. Hu, Y. Ba, W. Lu, Anti\u2010PD\u2010L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy\u2010refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study. Cancer 130, 3137\u20133146 (2024)","journal-title":"Cancer"},{"key":"4635_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00262-024-03715-4","volume":"73","author":"S Ren","year":"2024","unstructured":"S. Ren, A. Xiong, J. Yu et al. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study. Cancer Immunol. Immunother 73, 124 (2024)","journal-title":"Cancer Immunol. Immunother"},{"key":"4635_CR40","doi-asserted-by":"publisher","first-page":"19438","DOI":"10.1002\/cam4.6545","volume":"12","author":"S Zhang","year":"2023","unstructured":"S. Zhang, L. Yang, Y. Yang, G. Yang, H. Xu, X. Niu, Y. Wang, The efficacy and safety of chemo\u2010free therapy in epidermal growth factor receptor tyrosine kinase inhibitor\u2010resistant advanced non\u2010small cell lung cancer: A single\u2010arm, phase II study. Cancer Med. 12, 19438\u201319448 (2023)","journal-title":"Cancer Med."},{"key":"4635_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.lungcan.2020.11.007","volume":"151","author":"S Soni","year":"2021","unstructured":"S. Soni, A. Rastogi, K.T. Prasad, D. Behera, N. Singh, Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort. Lung Cancer 151, 16\u201319 (2021)","journal-title":"Lung Cancer"},{"key":"4635_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03564-z","volume":"22","author":"W Tian","year":"2024","unstructured":"W. Tian, Y. Ren, J. Lu et al. Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial. BMC Med. 22, 344 (2024)","journal-title":"BMC Med."},{"key":"4635_CR43","doi-asserted-by":"publisher","unstructured":"Zhu X., Ma X., Li H., et al (2025) The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced\/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096). Ann Med. https:\/\/doi.org\/10.1080\/07853890.2024.2443811","DOI":"10.1080\/07853890.2024.2443811"},{"key":"4635_CR44","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","volume":"16","author":"T Chu","year":"2021","unstructured":"T. Chu, R. Zhong, H. Zhong et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J. Thorac. Oncol. 16, 643\u2013652 (2021)","journal-title":"J. Thorac. Oncol."},{"key":"4635_CR45","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"E.S. Husebye, F. Castinetti, S. Criseno et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur. J. Endocrinol. 187, G1\u2013G21 (2022)","journal-title":"Eur. J. Endocrinol."},{"key":"4635_CR46","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1089\/thy.2021.0685","volume":"32","author":"T Mosaferi","year":"2022","unstructured":"T. Mosaferi, K. Tsai, S. Sovich, H. Wilhalme, N. Kathuria-Prakash, S.S. Praw, A. Drakaki, T.E. Angell, M.G. Lechner, Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from hashimoto\u2019s thyroiditis. Thyroid 32, 496\u2013504 (2022)","journal-title":"Thyroid"},{"key":"4635_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","volume":"17","author":"K Esfahani","year":"2020","unstructured":"K. Esfahani, A. Elkrief, C. Calabrese, R. Lapointe, M. Hudson, B. Routy, W.H. Miller, L. Calabrese, Moving towards personalized treatments of immune-related adverse events. Nat. Rev. Clin. Oncol. 17, 504\u2013515 (2020)","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4635_CR48","doi-asserted-by":"publisher","unstructured":"Poto R., Troiani T., Criscuolo G., Marone G., Ciardiello F., Tocchetti C.G., Varricchi G. (2022) Holistic approach to immune checkpoint inhibitor-related adverse events. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.804597","DOI":"10.3389\/fimmu.2022.804597"},{"issue":"6","key":"4635_CR49","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"J.R. Brahmer, H. Abu-Sbeih, P.A. Ascierto, J. Brufsky, L.C. Cappelli, F.B. Cortazar, D.E. Gerber, L. Hamad, E. Hansen, D.B. Johnson et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9(6), e002435 (2021). https:\/\/doi.org\/10.1136\/jitc-2021-002435","journal-title":"J. Immunother. Cancer"},{"key":"4635_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/thy.2023.0542","volume":"34","author":"K Tsai","year":"2024","unstructured":"K. Tsai, H. Ma, T.Z. Liang, Y. Xing, S. Chung, T. Dorff, D. Bell, M.G. Lechner, The combined effect of immune checkpoint inhibitors and tyrosine kinase inhibitors on thyroid function. Thyroid\u00ae 34, 158\u2013166 (2024)","journal-title":"Thyroid\u00ae"},{"issue":"10","key":"4635_CR51","doi-asserted-by":"publisher","first-page":"e011865","DOI":"10.1136\/jitc-2025-011865","volume":"13","author":"L Zhu","year":"2025","unstructured":"L. Zhu, Y.M. Cheung, C. Chiang, E.J. Gallagher, O.R. Hamnvik, J. Mammen, Z. Quandt, R. Jones, J. McDunn, H. Al-Bahadili et al. Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors. J. Immunother. Cancer 13(10), e011865 (2025). https:\/\/doi.org\/10.1136\/jitc-2025-011865","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"4635_CR52","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4103\/ijem.ijem_47_25","volume":"29","author":"R Rajan","year":"2025","unstructured":"R. Rajan, D. Nandakumar, Endocrine adverse events of immune checkpoint inhibitors: a comprehensive review. Indian. J. Endocrinol. Metab. 29(4), 408\u2013413 (2025). https:\/\/doi.org\/10.4103\/ijem.ijem_47_25","journal-title":"Indian. J. Endocrinol. Metab."},{"issue":"7","key":"4635_CR53","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00108-024-01731-1","volume":"65","author":"J Braegelmann","year":"2024","unstructured":"J. Braegelmann, D. F\u00fchrer, S. Tan, Endokrine nebenwirkungen von tumortherapien [endocrine side effects of tumor treatment]. Inn. Med. 65(7), 681\u2013689 (2024). https:\/\/doi.org\/10.1007\/s00108-024-01731-1. German","journal-title":"Inn. Med."},{"issue":"36","key":"4635_CR54","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"B.J. Schneider, J. Naidoo, B.D. Santomasso, C. Lacchetti, S. Adkins, M. Anadkat, M.B. Atkins, K.J. Brassil, J.M. Caterino, I. Chau et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39(36), 4073\u20134126 (2021). https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"4635_CR55","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EC-18-0068","volume":"7","author":"CE Higham","year":"2018","unstructured":"C.E. Higham, A. Olsson-Brown, P. Carroll, T. Cooksley, J. Larkin, P. Lorigan, D. Morganstein, P.J. Trainer; Society for Endocrinology Clinical Committee, Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr. Connect. 7(7), G1\u2013G7 (2018). https:\/\/doi.org\/10.1530\/EC-18-0068","journal-title":"Endocr. Connect."},{"issue":"2","key":"4635_CR56","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERC-18-0320","volume":"26","author":"F Castinetti","year":"2019","unstructured":"F. Castinetti, F. Albarel, F. Archambeaud, J. Bertherat, B. Bouillet, P. Buffier, C. Briet, B. Cariou, P. Caron, O. Chabre et al. French endocrine society guidance on endocrine side effects of immunotherapy. Endocr. Relat. Cancer 26(2), G1\u2013G18 (2019). https:\/\/doi.org\/10.1530\/ERC-18-0320","journal-title":"Endocr. Relat. Cancer"},{"issue":"12","key":"4635_CR57","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"J. Haanen, M. Obeid, L. Spain, F. Carbonnel, Y. Wang, C. Robert, A.R. Lyon, W. Wick, M. Kostine, S. Peters et al. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33(12), 1217\u20131238 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann. Oncol."},{"issue":"3","key":"4635_CR58","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","volume":"84","author":"S De Leo","year":"2023","unstructured":"S. De Leo, M. Trevisan, C. Moneta, C. Colombo, Endocrine-related adverse conditions induced by tyrosine kinase inhibitors. Ann. Endocrinol. 84(3), 374\u2013381 (2023). https:\/\/doi.org\/10.1016\/j.ando.2023.03.009","journal-title":"Ann. Endocrinol."},{"issue":"1","key":"4635_CR59","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"S. Shyam Sunder, U.C. Sharma, S. Pokharel, Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal. Transduct. Target. Ther. 8(1), 262 (2023). https:\/\/doi.org\/10.1038\/s41392-023-01469-6","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"18","key":"4635_CR60","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3390\/cells14181450","volume":"14","author":"T Tateno","year":"2025","unstructured":"T. Tateno, M. Shahidi, J.Q. Lu, C. Chik, The pituitary immune environment and immunotherapy: from hypophysitis to pituitary neuroendocrine tumors. Cells 14(18), 1450 (2025). https:\/\/doi.org\/10.3390\/cells14181450","journal-title":"Cells"},{"issue":"3","key":"4635_CR61","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/cancers17030436","volume":"17","author":"V Di Stasi","year":"2025","unstructured":"V. Di Stasi, D. La Sala, R. Cozzi, F. Scavuzzo, V. De Geronimo, M. Poggi, M. Vitale, A. Tortora, Immunotherapy-related hypophysitis: a narrative review. Cancers 17(3), 436 (2025). https:\/\/doi.org\/10.3390\/cancers17030436","journal-title":"Cancers"},{"issue":"5","key":"4635_CR62","doi-asserted-by":"publisher","first-page":"e220513","DOI":"10.1530\/EC-22-0513","volume":"12","author":"R Percik","year":"2023","unstructured":"R. Percik, S. Criseno, S. Adam, K. Young, D.L. Morganstein, Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer. Endocr. Connect. 12(5), e220513 (2023). https:\/\/doi.org\/10.1530\/EC-22-0513","journal-title":"Endocr. Connect."},{"issue":"2","key":"4635_CR63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/joim.12162","volume":"275","author":"ES Husebye","year":"2014","unstructured":"E.S. Husebye, B. Allolio, W. Arlt, K. Badenhoop, S. Bensing, C. Betterle, A. Falorni, E.H. Gan, A.L. Hulting, A. Kasperlik-Zaluska et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275(2), 104\u2013115 (2014). https:\/\/doi.org\/10.1111\/joim.12162","journal-title":"J. Intern. Med."},{"key":"4635_CR64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MED.0000000000000806","volume":"30","author":"V Siampanopoulou","year":"2023","unstructured":"V. Siampanopoulou, E. Tasouli, A. Angelousi, Diagnostic strategies in adrenal insufficiency. Curr. Opin. Endocrinol. Diabetes Obes. 30, 141\u2013153 (2023). https:\/\/doi.org\/10.1097\/MED.0000000000000806","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"4635_CR65","doi-asserted-by":"publisher","unstructured":"Helderman, N., Lucas, M., & Blank, C. (2023). Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors. Immuno-Oncology Technol., 17. https:\/\/doi.org\/10.1016\/j.iotech.2023.100374.","DOI":"10.1016\/j.iotech.2023.100374"},{"issue":"6","key":"4635_CR66","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1210\/js.2019-00136","volume":"3","author":"E Whittle","year":"2019","unstructured":"E. Whittle, H. Falhammar, Glucocorticoid regimens in the treatment of congenital adrenal hyperplasia: a systematic review and meta-analysis. J. Endocr. Soc. 3(6), 1227\u20131245 (2019). https:\/\/doi.org\/10.1210\/js.2019-00136","journal-title":"J. Endocr. Soc."},{"issue":"Suppl 1","key":"4635_CR67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4274\/jcrpe.galenos.2024.2024-6-23-S","volume":"17","author":"F Bu\u011frul","year":"2025","unstructured":"F. Bu\u011frul, N. \u00d6zcan Murat, Treatment and follow-up of non-stress adrenal insufficiency. J. Clin. Res. Pediatr. Endocrinol. 17(Suppl 1), 93\u2013101 (2025). https:\/\/doi.org\/10.4274\/jcrpe.galenos.2024.2024-6-23-S. Jan 10","journal-title":"J. Clin. Res. Pediatr. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04635-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04635-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04635-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:58:50Z","timestamp":1781650730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04635-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4635"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04635-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"153"}}